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Studies of the roles of variants of the IGF-I gene in the regu-
lation of bone mineral density (BMD) have yielded conflicting
results. We examined the role of a microsatellite repeat poly-
morphism in one of the promoter regions of the IGF-I gene in
relation to femoral BMD in elderly women and men from the
Rotterdam Study. We studied 5648 and 4134 individuals at
baseline and follow-up (2 yr later), respectively. Femoral
BMD measurements were performed using dual energy x-ray
absorptiometry. In women, baseline BMD levels were, on the
average, 0.02 g/cm2 [95% confidence interval (CI) for differ-
ence, 0.03, 0.00 g/cm2] lower in individuals without the
192-bp allele as compared with the homozygotes for the allele
(P  0.03). The mean rate of BMD change from baseline to
follow-up was 6.9 mg/cm2 (95% CI, 10.8, 3.0), 4.5 mg/cm2
(95% CI, 6.4, 2.5), and 2.3 mg/cm2 (95% CI, 4.2, 0.3) in
noncarriers, heterozygotes, and homozygotes for the 192-bp
allele, respectively (P trend  0.03). Adjustment for age and
body mass index did not essentially change this relation. No
such effects were observed in men. Our findings suggest that
this promoter polymorphism or another functional polymor-
phism in linkage disequilibrium may be a genetic determinant
of BMD levels and rate of bone loss in postmenopausal women.
(J Clin Endocrinol Metab 88: 3878–3884, 2003)
OSTEOPOROSIS HAS BEEN defined as a systemic skel-etal disease characterized by low bone mineral den-
sity (BMD) and microarchitectural deterioration of bone tis-
sue, with a consequent increase in bone fragility and
susceptibility to fracture (1). From the genetic perspective,
BMD is a complex trait determined by the peak bone mass
achieved during adulthood and the subsequent rate of bone
loss with age. Heritability estimates for BMD have been
reported to be high, ranging between 50 and 80% (2, 3). The
contribution of genetic factors to the regulation of bone loss
has been much less well studied, and data are conflicting (4).
Although Christian et al. (5) found no evidence of a genetic
effect on radial (cortical) bone in aging male twins, Kelly et
al. (6) reported a significant genetic effect on changes in axial
bone density in adult twins. It has become clear that there is
not one major single gene responsible for the risk of osteo-
porosis (3). Rather, an individual’s susceptibility to develop
osteoporosis is determined, as in most common diseases, by
several common gene variants with modest, but real, genetic
effects (7). The regulation of bone mass depends on several
factors, including the balance between the amount of bone
resorbed by osteoclasts and the amount of bone formed by
osteoblasts. Genes involved in the mechanisms that control
the differentiation and function of these cells may be deter-
minants of BMD and osteoporosis. One approach to identify
individual genetic factors is the so-called candidate gene
approach. To date, several genes have been investigated,
including the vitamin D receptor, collagen type I1
(COL11), IL-6, and TGF genes among others. Of these,
only the COL11 gene has been found associated to BMD
and fracture risk in a consistent way, as illustrated by two
meta-analyses (8, 9). The IGF-I gene has also been considered
a candidate gene based on its important role in bone
metabolism.
IGF-I is a ubiquitous polypeptide that stimulates osteo-
blast activity, subsequently leading to bone matrix formation
and inhibition of bone collagen degradation (10). IGF-I also
stimulates osteoclast formation and action (11). Plasma levels
of IGF-I decrease with age in both males and females. Re-
duced plasma levels have been associated with low BMD
(12–14), osteoporosis (15), and fractures (16), although it is
not known whether these systemic levels are representative
of local skeletal concentrations (17–19).
Several polymorphisms (20–22) have been identified in the
IGF-I gene (map location 12q22-q24.1) and in the 5-flanking
promoter region extending up to 1630 bp upstream of the
transcription initiation site of exon 1 (23–26). On position
684 of this promoter region lies a (CA)n microsatellite re-
peat polymorphism (27). Earlier we found that birth weight
(28, 29), body height, and serum levels of IGF-I after age 55
yr (30) increased with the number of 192-bp alleles in the
genotype for this polymorphism. Further, subjects without
this wild-type allele had increased risk for type 2 diabetes
and myocardial infarction (30).
The results of genetic studies regarding the relation of this
polymorphism to osteoporosis and BMD have been contro-
Abbreviations: BMD, Bone mineral density; BMI, body mass index;
CI, confidence interval; DEXA, dual energy x-ray absorptiometry.
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versial. Rosen et al. (31) reported that the 192-bp/192-bp ge-
notype was more prevalent in 25 Caucasian men with idio-
pathic osteoporosis than in controls. In the same study,
healthy men with this genotype tended (P  0.15) to have
lower BMD t scores. In 314 healthy postmenopausal Japanese
women, Miyao et al. (32) found no association between BMD
and the IGF-I promoter genotypes. In contrast, Kim et al. (33)
found that a genotype based on one of the major alleles of the
polymorphism was related to spinal and femoral BMD in 300
postmenopausal Korean women. In a study in 542 female
sibling pairs and 363 premenopausal women, Takacs et al.
(34) found no evidence for a relation between femoral or
spinal BMD and the IGF-I gene locus or the (CA)n micro-
satellite repeat polymorphism.
Given these inconsistent reports and our previous findings
on the relation of this IGF-I gene promoter polymorphism to
serum IGF-I levels, height, type 2 diabetes mellitus (30), and
birth weight (28), we examined the role of the 192-bp allele
in relation to BMD and rate of bone loss in a large population-
based cohort.
Experimental Subjects
Subjects were derived from the Rotterdam Study, a single-center,
prospective, population-based study of determinants of chronic dis-
abling diseases in the elderly (aged 55 yr and over). Written informed
consent was obtained from every participant. The design of the study has
been described previously (35). In an attempt to evaluate all 7983 par-
ticipants from the Rotterdam study, 7012 (87.9%) subjects were geno-
typed for the polymorphism (27) in the promoter region of the human
IGF-I gene. From the 971 individuals not genotyped, 848 had no blood
sample to isolate DNA for the analysis, and in the remaining 123 we
failed to obtain a genotype after multiple attempts.
Materials and Methods
The analysis was performed in two phases. In the first phase (base-
line), all individuals with complete BMD and anthropometric measure-
ments (n 5648) were used for a cross-sectional analysis of femoral BMD
levels. In the second phase (follow-up), subjects who had complete BMD
measurements both at baseline and on the follow-up visit (n  4134)
were used to study the yearly rate of change in BMD.
Measurements
Age was calculated for each individual from the date of birth and the
date of BMD bone scan. Three 10-yr strata were defined, starting at age 55
yr. Height (centimeters) and weight (kilograms) were measured in a stand-
ing position wearing indoor clothes without shoes. Body mass index (BMI;
kilograms per meter squared), was calculated as weight divided by the
square of height. BMD measurements (grams per square centimeter) of the
proximal femur were performed by dual energy x-ray absorptiometry
(DEXA) using a DPX-L densitometer (Lunar Radiation Corp., Madison,
WI). Methods, quality assurance, accuracy, and precision issues of the
DEXA measurements have been described previously (36).
Approximately 2 yr (mean, 23.8 months; sd, 7.0) after the baseline
scan, follow-up BMD measurements were performed using identical
procedures. The rate of change in BMD (milligrams per square centi-
meter per year) was calculated as the difference between baseline and
follow-up BMD divided by the time (in years) elapsed between mea-
surements (and multiplied by a factor of 1000 for scale convenience).
Genotyping
PCR was performed using oligonucleotide primers designed to am-
plify the polymorphic (CA)n repeat 1 kb upstream of the human IGF-I
gene. The reaction was carried out in a final volume of 7.5 l containing
25 ng genomic DNA obtained from peripheral white blood cells and
extracted by standard proteinase K digestion and salting-out procedure
(37), 5 pmol forward primer (5-ACCACTCTGGGAGAAGGGTA-3),
0.5 pmol reverse primer (5-GCTAGCCAGCTGGTGTTATT-3), 25 mm
deoxy-NTP, 2.2 mm MgCl2, 0.01% W1 (Invitrogen, San Diego, CA), and
0.4 U Taq DNA polymerase (Invitrogen). PCR was performed in 384-well
plates (94 C for 5 min; 35 PCR cycles of 30 sec at 94 C, 30 sec at 55 C,
and 30 sec at 72 C; 72 C for 7 min; 4 C hold). Forward primers were
labeled with FAM, HEX, or NED to determine the size of PCR products
by fragment analysis on an automated sequencing apparatus (ABI 377
Genescan software version 3.1, PE Applied Biosystems, Foster City, CA;
6.25% longranger gel, filter set D, predefined categories according to size
and labeling of peak height between 100 and 2000 bp, each lane con-
taining three samples). The sizes of the PCR products were determined
in comparison with the internal ROX 500-size standard (PerkinElmer,
Norwalk, CT). The two highest peaks were labeled (binned) with Geno-
typer software version 2.5. The automatic binning was reviewed by two
independent observers in separate files from the same gel, which were
subsequently cross-checked. Discordant binned samples were geno-
typed again. From sequence analysis it is known that the allele with
length 192-bp (wild-type in our population) corresponds to 19 CA re-
peats (CA(19)). Based on the relationship between the polymorphism and
serum IGF-I levels, genotypes were assembled from two allele categories
as described by Vaessen et al. (30): the 192-bp allele and all other alleles
pooled as non-192-bp alleles. This resulted in three groups of individuals:
homozygotes for the 192-bp allele, heterozygotes for the 192-bp allele,
and noncarriers of the 192-bp allele.
Statistical analysis
Genotype and allele frequencies of the IGF-I promoter polymorphism
were determined, and the genotype frequencies were tested for Hardy-
Weinberg equilibrium proportions using the ARLEQUIN package (38).
Analyses specifying risk genotypes with other alleles showed no sig-
nificant associations, but were consistent with the 192-bp allele approach
used.
In both the baseline and follow-up analyses, means and sds were
computed for all measurements and compared with those of the same
gender in the reference population using t tests. Subsequently, stratified
analyses by gender (and age groups) were performed. Multiple linear
regression was used to model the relation with BMD and rate of BMD
change adjusted for age, BMI, and baseline BMD (in the follow-up
analysis). Possible interactions between genotypes and covariates were
explored in plots and tested in the linear regression models including
product terms. Trend analysis, assuming an underlying additive genetic
model (39), was performed for the presence of zero, one, or two copies
of the associated allele, incorporating the genotype variable as a con-
tinuous term in the multiple linear regression models. Finally, model
assumptions were verified, and model residuals were checked for good-
ness of fit. If not stated otherwise, all analyses were performed using
SPSS package version 10 (SPSS, Inc., Chicago, IL).
Results
Allele and 192-bp genotype frequencies are shown in Table
1. No significant deviations of the frequencies were observed
among the baseline and follow-up groups. All genotype fre-
quencies were in Hardy-Weinberg equilibrium proportions.
In men and women, allele frequencies were stable over age
categories (data not shown).
Table 2 compares the characteristics of women and men in
the two analytical phases with all women and men of the
Rotterdam study (reference population n  7983). Overall,
women showed a lower BMD at baseline and a higher rate of
BMD loss than men. The BMD levels of the group used for the
baseline analysis were slightly lower than those in the group
used for the follow-up analysis. The use of concurrent estrogen
replacement therapy or bone modulators in women is very low.
When analyzing cross-sectional baseline BMD measure-
ments in females, the IGF-I polymorphism accounted for
0.2% of the variance (r2) in BMD levels. Mean femoral neck
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BMD adjusted for age and BMI (Fig. 1) increased with the
number of 192-bp alleles in the genotypes (P for trend 0.02).
BMD was, on the average, 0.02 g/cm2 [95% confidence in-
terval (CI) for difference, 0.03, 0.00 g/cm2] lower in
women without the 192-bp allele than in homozygotes for the
allele (P  0.03). This effect was also consistent at the other
femoral sites (P for trend  0.01 and P  0.01 for the tro-
chanter and Ward’s triangle, respectively). When analyzing
in age strata (Fig. 2), this effect was only observed in women
older than 65 yr; the differences between homozygous
women and noncarriers of the 192-bp allele were 0.02
g/cm2 (95% CI, 0.04, 0.00 g/cm2) and 0.04 g/cm2 (95%
CI, 0.07, 0.01 g/cm2) for the 65–75 and 75 yr and older age
categories, respectively. The interaction between IGF-I ge-
notype and age was borderline significant (P for interac-
tion  0.06). There was no significant interaction of IGF-I
genotype and BMI (data not shown). No such dose effect on
baseline BMD was observed in males overall (Fig. 3) or
within age groups (data not shown).
At follow-up, the rate of change in mean BMD observed
in the period between the baseline and follow-up measure-
ments was analyzed. In women, the IGF-I promoter geno-
type accounted for 0.1% of the variance (r2) in BMD change.
The mean rate of BMD change per year showed a significant
inverse trend (P  0.03) according to the number of 192-bp
alleles in the genotype: 6.9 mg/cm2 (95% CI, 10.8, 3.0)
in women carrying zero and 4.5 mg/cm2 (95% CI, 6.4,
2.5) in women carrying one (heterozygotes) and2.3 mg/
cm2 (95% CI, 4.2, 0.3) in women carrying two copies (ho-
mozygotes) of the 192-bp allele, respectively (Fig. 4). Also in
women this trend was consistent through all age strata (data
not shown). Adjustment for baseline BMD did not essentially
modify the results (data not shown). In males, no such trend
effect was observed in the follow-up analysis, overall or
within age groups (data not shown).
Discussion
This population-based study in elderly individuals
showed that in women the absence of the wild-type (192-bp)
TABLE 1. Allele and 192-bp genotype frequency distributions of the study populations
Polymorphism Reference
Total (%);
(n  7012)a
Baseline analysis (%) Follow-up analysis (%)
Length PCR product (bp) (CA)n Total
(n  5648)
Females
(n  3265)
Males
(n  2383)
Total
(n  4134)
Females
(n  2341)
Males
(n  1793)
198 22 1.6 1.5 1.4 1.6 1.5 1.4 1.5
196 21 6.8 6.8 6.9 6.8 6.8 6.7 7.0
194 20 19.1 19.4 19.4 19.4 19.5 19.8 19.1
192 19 65.9 65.7 65.5 66.1 65.7 65.3 66.3
190 18 4.4 4.4 4.5 4.2 4.3 4.4 4.1
188 17 1.7 1.7 1.7 1.7 1.7 1.8 1.6
Other rare allelesb 0.5 0.5 0.5 0.3 0.4 0.4 0.4
Genotypes
Homozygous 192 bp 43.7 43.5 43.2 44.0 43.7 43.3 44.1
Heterozygous 192 bp 44.3 44.4 44.6 44.2 44.1 44.0 44.3
No 192 bp homozygous 12.0 12.1 12.2 11.8 12.2 12.7 11.6
a All Rotterdam Study participants genotyped for the IGF-I promoter polymorphism.
b 174-bp CA10, 176-bp CA11, 186-bp CA16, and 200-bp CA23.
TABLE 2. Characteristics of the study populations
Measurements
Reference Baseline analysis Follow-up analysis
Total
(n  7983)
Females
(n  4878)
Males
(n  3105)
Females
(n  3265)
Males
(n  2383)
Females
(n  2341)
Males
(n  1793)
Age (yr) 70.6 (9.8) 71.7 (10.3) 69.0 (8.7) 68.3a (8.2) 67.5a (7.6) 69.2a (7.7) 68.6 (7.3)
Height (cm)b 166.6 (9.5) 161.1 (6.8) 174.6 (6.8) 161.7 (6.5) 174.9 (6.8) 162.0 (6.4) 175.2 (6.6)
Weight (kg)b 73.7 (11.6) 69.9 (10.9) 78.7 (10.6) 69.9 (10.9) 78.7 (10.6) 70.1 (10.7) 79.4 (10.9)
BMI (kg/m2)b 26.3 (3.6) 26.8 (4.0) 25.7 (3.0) 26.8 (4.0) 25.7 (2.9) 26.7 (3.9) 25.9 (2.9)
Time since menopause (yr) 21.2 (11.0) 18.7a (9.5) 19.4a (9.1)
HRTc or bone modulators (%) 2.0 2.7 2.8
BMD (g/cm2)
Femoral neckd 0.84 (0.14) 0.81 (0.13) 0.88 (0.13) 0.81 (0.13) 0.88 (0.13) 0.82 (0.13) 0.88 (0.13)
Word triangled 0.70 (0.15) 0.67 (0.15) 0.73 (0.15) 0.67 (0.15) 0.73 (0.15) 0.68 (0.15) 0.74 (0.14)
Trochanterd 0.78 (0.15) 0.72 (0.13) 0.85 (0.14) 0.72 (0.13) 0.85 (0.14) 0.73 (0.13) 0.85 (0.13)
BMD change
Femoral necke
Absolute (g/cm2-yr) 0.004 (0.03) 0.004 (0.03) 0.003 (0.03) 0.004 (0.04) 0.003 (0.03)
Relative (% of baseline-yr) 1.2 (10.3) 1.2 (12.2) 1.1 (7.3) 1.1 (12.3) 1.0 (7.2)
Data are unadjusted means (SD) or (%).
a P  0.01.
b Hormone replacement therapy.
c Based on 6917 individuals with present antropometric measurements.
d Based on 5823 individuals with present BMD measurements.
e Based on 4331 individuals with present BMD measurements.
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allele in a (CA)n repeat polymorphism in the promoter region
of the IGF-I gene is associated with lower BMD levels and
higher rates of bone loss at the different femoral sites. No
associations were observed in men at any femoral site of
BMD measurement.
Our findings of decreased BMD levels and faster rate of
bone loss in the absence of the 192-bp allele are in agreement
with the association reported earlier, where the absence of
the 192-bp allele was associated with lower total IGF-I serum
levels (30). Results from that study may be extrapolated to
our present study, because it was performed in a random
subset of our current study population. Further, we have
recently reported that this promoter polymorphism influ-
ences the age-related decline in IGF-I levels (40).
The strengths of our study design include its population-
based nature, ethnic homogeneity, large sample size, gender-
stratified analysis, and defined age range (elderly/post-
menopausal). BMD characteristics in this study are similar to
those reported previously in our population (36). As indi-
viduals were selected on the basis of having complete BMD
measurements at baseline or at follow-up, we recognize the
possibility of selection bias. Individuals whose BMD was not
measured in the Rotterdam Study were older and probably
had higher morbidity, and, if measured, would presumably
have had lower BMD than those in the study. However, there
is no evidence for genotype selection in our population, as
allele frequencies were virtually the same in the various
study groups and in the genotypic reference population, and
they remained stable with age. Similarly, the bias arising
from the individuals not genotyped for the polymorphism
seems to be random from the genetic perspective, as our
allele frequencies are similar to those reported in other Cau-
casian populations (27, 34).
The short follow-up time (2 yr) used to evaluate the rate
of BMD change limits the power to assess differences among
individuals. However, the 192-bp allele dose effect of our
follow-up analysis is in agreement with our cross-sectional
analysis in the sense that the presence of the 192-bp allele
relates to higher BMD levels and lower rates of bone loss.
The gender specificity of our findings is in concordance
with the association between IGF-I levels and BMD reported
earlier by Barrett-Connor et al. (14). It is not explained by
differential survival between sexes in our population, as
genotype and allele frequency distributions were similar in
men and women in different age categories. Most likely, our
findings seem to identify differential responses of the geno-
types to the postmenopausal bone loss caused by estrogen
deficiency (41). As differences in estrogen levels influence the
IGF-I regulatory axis (42–45), the hypoestrogenic state in-
flicted by the menopausal process in women may be (in the
absence of concurrent osteoporotic treatment, i.e. hormone
replacement therapy) directly modulating the observed
IGF-I genotype effect on the rate of bone loss and BMD level.
Anyway, it is unlikely that estrogen deficiency explains most
of the decline in IGF-I levels with age, as IGF-I levels begin
to fall in both genders long before the age of menopause (14).
Alternatively, genetically determined variations in body
composition with aging could also be indirectly related to the
observed genotype effect. Although the genotype-dependent
differential rate of bone loss is observed from age 55 yr, the
genotype effect on BMD levels is only evident after age 65 yr.
This may reflect the time it takes for these genotype effects
FIG. 1. Baseline mean BMD of the femoral neck within 192-bp ge-
notype groups in women. Data are adjusted for age and BMI.
FIG. 2. Baseline mean BMD of the femoral
neck within 192-bp genotype groups and age
categories in women. Data are adjusted for
age and BMI.
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(during postmenopausal estrogen deficiency) to become de-
tectable on BMD differences. Evaluation of possible biolog-
ical interactions of the IGF-I gene with genes and proteins
related to estrogen metabolism might provide further
insight.
Not observing the 192-bp allele dose effect in males may be
attributed to various mechanisms. In elderly men, estrogen
levels are higher compared with postmenopausal women
(46), which might also affect the rate of bone loss, making
age-related increases in bone turnover less pronounced in
men (47). Similarly, from the perspective of bone size and
architecture (48), both genders have an age-related decline in
bone material properties, but men exhibit greater compen-
sating bone-remodeling patterns (subperiosteal expansion
and bone apposition at the femoral diaphysis). These differ-
ences in bone geometry are reflected in BMD measurements,
as DEXA adjusts for the scanned area, but does not correct
for the fact that wider bones are also thicker, resulting in
greater BMD even if the actual density of bone tissue is not
different (49). This way, our analysis could not discriminate
changes in BMD due to variations in bone mineral from those
caused by changes in bone geometry. Interestingly, Looker
et al. (48) postulated previously that IGF-I could be related to
the gender differences evidenced in bone geometry with
aging.
Previous studies have either failed to identify associations
between this polymorphism and BMD or are conflicting.
There are differences in study design that may explain this.
Takacs et al. (34) included in their association analysis a
population of premenopausal women, compared with the
postmenopausal population studied by us. Furthermore, the
failure to identify linkage of this polymorphism to BMD in
their sibling pair analysis may be explained by lack of power
given the complexity of the trait and the relatively small
effect size of the IGF-I polymorphism. Although Miyao et al.
(32) and Kim et al. (33) included postmenopausal women in
their study, we face caveats to compare our findings with
theirs. Differences exist between the Dutch and both Japa-
nese and Korean populations in allele and genotype fre-
quencies, in linkage disequilibrium and in racial phenotypes.
FIG. 3. Baseline mean BMD of the femoral neck
within 192-bp genotype groups in men. Data are
adjusted for age and BMI.
FIG. 4. Mean BMD change in the femoral neck
within 192-bp genotype groups in women. Data
are adjusted for age, BMI, and baseline BMD.
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In contrast to our findings, Rosen et al. (31) associated the
presence of the 192-bp allele with lower total IGF-I serum
levels and male osteoporosis. Male patients with idiopathic
osteoporosis represent a very distinct phenotypic trait com-
pared with the estrogen-deficient osteopenia inflicted by
menopause (41), which together with differences in power,
might contribute to apparent contradictory results.
Given the population-based approach of our study, we
cannot distinguish whether this polymorphism itself is in-
volved in the regulation of IGF-I expression or merely flags
another polymorphism in the promoter region functionally
involved in IGF-I expression. If the latter is true, this may be
an explanation for inconsistent findings in the association
studies of this polymorphism with BMD (31–34) and other
outcomes (50), because linkage disequilibrium can differ be-
tween populations.
In summary, we found in postmenopausal women a small,
but significant, effect between an IGF-I gene promoter poly-
morphism and both BMD and (short-term) rates of bone loss.
The presence of the wild-type (192-bp) allele in the genotype
was associated with higher BMD and lower rate of bone loss.
This genotypic effect on BMD in women may therefore sug-
gest a relation between IGF-I activity and bone loss due to
estrogen deficiency. In men, no effect was observed, prob-
ably due to gender differences in the age-related hormonal
changes affecting bone turnover rates, bone size, and bone
architecture. This population-based study provides substan-
tial evidence to link genetically determined levels of IGF-I to
BMD in Caucasian postmenopausal women.
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